Skip to main content
Equibles
NVCR logo

NVCR · NovoCure Ltd · Metrics

Track NVCR — free

Use NVCR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVCR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.66 -0.05 (-0.32%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.83B
Shares
116.45M
Volume · Oct 21 928.25K Avg daily vol (3M) 1.47M

NVCR metrics

94 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.71
Market cap
$1.83B

Price action

20 metrics
Price change (1W)
+9.9%
Price change (30D)
-5.0%
Price change (3M)
-1.8%
Price change (6M)
+28.5%
Price change (YTD)
+21.5%
Price change (1Y)
+8.5%
Trailing year
Price change (5Y)
-86.7%
52-week high
$19.99
52-week low
$10.03
Change from 52-week high
-21.4%
Change from 52-week low
+56.6%
Annualized volatility
80.0%
Annualized volatility (3M)
78.7%
Beta
1.5
RSI (14D)
53.5
Price vs SMA 50
-3.6%
Price vs SMA 200
+6.1%
Avg volume (3M)
1.47M
Relative volume
1.2
Average dollar volume
$24.36M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
116.45M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.6×
reciprocal yield 38.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.5×
reciprocal yield 40.3%
P / book
5.1
reciprocal yield 19.5%
FCF yield
-1.5%
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-8.6%

Historical valuation

8 metrics
P / E historical average (3Y)
933.0×
reciprocal yield 0.1%
P / E historical average (5Y)
933.0×
reciprocal yield 0.1%
EV / revenue historical average (3Y)
9.8×
reciprocal yield 10.2%
EV / revenue historical average (5Y)
15.0×
reciprocal yield 6.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
2,613.9×
reciprocal yield 0.0%
EV / EBITDA historical average (5Y)
2,613.9×
reciprocal yield 0.0%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-10-29
Last earnings
2026-07-23

Profitability

9 metrics
Gross margin
76.1%
Operating margin
-22.1%
Trailing 12 months
Net margin
-21.2%
Gross profit (TTM)
$532.27M
Operating profit (TTM)
−$154.40M
Net income (TTM)
−$148.56M
Trailing 12 months
Diluted EPS (TTM)
$-1.30
FCF margin
-3.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$6.16
Gross profit per diluted share (TTM)
$4.69
Operating profit per diluted share (TTM)
$-1.36
EBITDA per diluted share (TTM)
$-1.22
Net income per diluted share (TTM)
$-1.31
Operating cash flow per diluted share (TTM)
$-0.03
Free cash flow per diluted share (TTM)
$-0.22
Capital expenditures per diluted share (TTM)
$0.20
R&D per diluted share (TTM)
$1.98
Stock compensation per diluted share (TTM)
$1.14
Book value per share
$3.03

Growth

11 metrics
Revenue growth YoY
+15.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$699.19M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.0%
Year over year · more shares
Revenue CAGR (3Y)
+6.8%
Revenue CAGR (5Y)
+5.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-43.9%
Return on assets
-18.7%
Debt / equity
0.6
Current ratio
2.9
EBITDA (TTM)
−$138.08M
Free cash flow (TTM)
−$25.43M
Quick ratio
2.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$101.50M
Latest balance sheet
Cash & equivalents
$93.70M
Total assets
$795.19M
Total debt
$195.05M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.81M
Capital expenditures (TTM)
$22.62M
R&D (TTM)
$224.72M
SG&A (TTM)
—
Stock compensation (TTM)
$129.16M
R&D / revenue
32.1%
Stock compensation / revenue
18.5%

Ownership (13F)

9 metrics
13F filers
218
13F filer change QoQ
-7
Institutional ownership
89.8%
Conviction holders (share of 13F filers)
0.5%
Crowding (high-turnover and private-fund holders)
25.0%
Private-fund adviser ownership
14.3%
Active holders' share change QoQ
+4.9%
Holder tenure
14.4
Price vs estimated holder cost
-9.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.5%

Short interest

3 metrics
Short interest
9.6%
Latest settlement · 10.1 days to cover
Days to cover
10.1d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1645113 CUSIP G6674U108 13F (30d) 22 filings 22 filers Visit website Investor relations